2 Safe Growth Stocks to Buy for 2022

46
6
Favorite

2 Safe Growth Stocks to Buy for 2022

Motley Fool2022-01-06

This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（6）

Uasbau
·2022-01-07
Like
Reply
Like
Report
GANCL
·2022-01-07
For long term investment
Reply
3
Report
Sugi89
·2022-01-06
Everytime I follow your lead, Only reds no greens
Reply
2
Report
Bluefish
·2022-01-06
Great
Reply
4
Report
Tadalada
·2022-01-06
Pls like
Reply
5
Report
Jer_Soul
·2022-01-06
[Cry]
Reply
2
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2201269899?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-06 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2201269899","market":"us","top_or_hot":-1,"title":"2 Safe Growth Stocks to Buy for 2022","media":"Motley Fool","content":"<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","article_id":"2201269899","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","pubTimestamp":1641474113,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4507":"流媒体概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4551":"寇图资本持仓","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","BK4077":"互动媒体与服务","BK4527":"明星科技股","BK4524":"宅经济概念","BK4503":"景林资产持仓","BK4566":"资本集团","BK4525":"远程办公概念","ABT":"雅培","BK4504":"桥水持仓","BK4553":"喜马拉雅资本持仓","BK4554":"元宇宙及AR概念"},"translate_title":"2022年购买2只安全成长股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FB":1,"ABT":1},"content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9006013710,"gmtCreate":1641550337280,"gmtModify":1676533628179,"author":{"id":"3581724772671504","authorId":"3581724772671504","name":"Uasbau","avatar":"https://static.tigerbbs.com/67cdf409f2239595269918513a5faac9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581724772671504","authorIdStr":"3581724772671504"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006013710","repostId":2201269899,"repostType":2,"repost":{"id":"2201269899","kind":"highlight","pubTimestamp":1641474113,"share":"https://ttm.financial/m/news/2201269899?lang=&edition=fundamental","pubTime":"2022-01-06 21:01","market":"us","language":"en","title":"2 Safe Growth Stocks to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","media":"Motley Fool","summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","content":"<html><head></head><body><p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.</p><p>However, there are two growth stocks that look to be fairly safe bets to do well this year: <b>Abbott Laboratories </b>(NYSE:ABT) and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB). These industry giants don&#39;t lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.</p><h2>1. Abbott Laboratories</h2><p>Abbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests &#34;performed at equivalent sensitivity as other variants.&#34;</p><p>For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company&#39;s business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.</p><p>When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor&#39;s offices and hospitals are back to their normal operations.</p><p>Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the <b>S&amp;P 500</b> has increased by a more modest 281%. Even though Abbott has already outperformed the S&amp;P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.</p><h2>2. Meta Platforms</h2><p>Meta Platforms may be trying to bank on the emergence of the metaverse, but that&#39;s not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.</p><p>Proof of the company&#39;s resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.</p><p>Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there&#39;s no real competition out there that Facebook faces, which is why it&#39;s such a safe investment for the foreseeable future.</p><p>Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company&#39;s net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.</p><p>It&#39;s almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT":"雅培","BK4525":"远程办公概念","BK4566":"资本集团","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4524":"宅经济概念","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201269899","content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008559119,"gmtCreate":1641488520757,"gmtModify":1676533620765,"author":{"id":"3566524239552357","authorId":"3566524239552357","name":"GANCL","avatar":"https://static.tigerbbs.com/02bdb0309baf16b47e74509dc75824e6","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3566524239552357","authorIdStr":"3566524239552357"},"htmlText":"For long term investment&nbsp;","listText":"For long term investment&nbsp;","text":"For long term investment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008559119","repostId":2201269899,"repostType":4,"repost":{"id":"2201269899","kind":"highlight","pubTimestamp":1641474113,"share":"https://ttm.financial/m/news/2201269899?lang=&edition=fundamental","pubTime":"2022-01-06 21:01","market":"us","language":"en","title":"2 Safe Growth Stocks to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","media":"Motley Fool","summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","content":"<html><head></head><body><p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.</p><p>However, there are two growth stocks that look to be fairly safe bets to do well this year: <b>Abbott Laboratories </b>(NYSE:ABT) and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB). These industry giants don&#39;t lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.</p><h2>1. Abbott Laboratories</h2><p>Abbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests &#34;performed at equivalent sensitivity as other variants.&#34;</p><p>For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company&#39;s business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.</p><p>When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor&#39;s offices and hospitals are back to their normal operations.</p><p>Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the <b>S&amp;P 500</b> has increased by a more modest 281%. Even though Abbott has already outperformed the S&amp;P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.</p><h2>2. Meta Platforms</h2><p>Meta Platforms may be trying to bank on the emergence of the metaverse, but that&#39;s not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.</p><p>Proof of the company&#39;s resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.</p><p>Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there&#39;s no real competition out there that Facebook faces, which is why it&#39;s such a safe investment for the foreseeable future.</p><p>Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company&#39;s net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.</p><p>It&#39;s almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT":"雅培","BK4525":"远程办公概念","BK4566":"资本集团","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4524":"宅经济概念","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201269899","content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008272440,"gmtCreate":1641475221860,"gmtModify":1676533618777,"author":{"id":"3555463959828345","authorId":"3555463959828345","name":"Sugi89","avatar":"https://static.tigerbbs.com/84e333131102918751db4ab138b3b92b","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3555463959828345","authorIdStr":"3555463959828345"},"htmlText":"Everytime I follow your lead, Only&nbsp;reds no&nbsp;greens","listText":"Everytime I follow your lead, Only&nbsp;reds no&nbsp;greens","text":"Everytime I follow your lead, Only reds no greens","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008272440","repostId":2201269899,"repostType":4,"repost":{"id":"2201269899","kind":"highlight","pubTimestamp":1641474113,"share":"https://ttm.financial/m/news/2201269899?lang=&edition=fundamental","pubTime":"2022-01-06 21:01","market":"us","language":"en","title":"2 Safe Growth Stocks to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","media":"Motley Fool","summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","content":"<html><head></head><body><p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.</p><p>However, there are two growth stocks that look to be fairly safe bets to do well this year: <b>Abbott Laboratories </b>(NYSE:ABT) and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB). These industry giants don&#39;t lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.</p><h2>1. Abbott Laboratories</h2><p>Abbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests &#34;performed at equivalent sensitivity as other variants.&#34;</p><p>For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company&#39;s business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.</p><p>When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor&#39;s offices and hospitals are back to their normal operations.</p><p>Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the <b>S&amp;P 500</b> has increased by a more modest 281%. Even though Abbott has already outperformed the S&amp;P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.</p><h2>2. Meta Platforms</h2><p>Meta Platforms may be trying to bank on the emergence of the metaverse, but that&#39;s not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.</p><p>Proof of the company&#39;s resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.</p><p>Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there&#39;s no real competition out there that Facebook faces, which is why it&#39;s such a safe investment for the foreseeable future.</p><p>Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company&#39;s net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.</p><p>It&#39;s almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT":"雅培","BK4525":"远程办公概念","BK4566":"资本集团","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4524":"宅经济概念","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201269899","content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008271448,"gmtCreate":1641474426428,"gmtModify":1676533618699,"author":{"id":"3574724399840291","authorId":"3574724399840291","name":"Bluefish","avatar":"https://community-static.tradeup.com/news/331df3ab3ccfe360e355f6cafc80b768","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":1,"idStr":"3574724399840291","authorIdStr":"3574724399840291"},"htmlText":"Great&nbsp;","listText":"Great&nbsp;","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008271448","repostId":2201269899,"repostType":4,"repost":{"id":"2201269899","kind":"highlight","pubTimestamp":1641474113,"share":"https://ttm.financial/m/news/2201269899?lang=&edition=fundamental","pubTime":"2022-01-06 21:01","market":"us","language":"en","title":"2 Safe Growth Stocks to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","media":"Motley Fool","summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","content":"<html><head></head><body><p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.</p><p>However, there are two growth stocks that look to be fairly safe bets to do well this year: <b>Abbott Laboratories </b>(NYSE:ABT) and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB). These industry giants don&#39;t lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.</p><h2>1. Abbott Laboratories</h2><p>Abbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests &#34;performed at equivalent sensitivity as other variants.&#34;</p><p>For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company&#39;s business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.</p><p>When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor&#39;s offices and hospitals are back to their normal operations.</p><p>Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the <b>S&amp;P 500</b> has increased by a more modest 281%. Even though Abbott has already outperformed the S&amp;P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.</p><h2>2. Meta Platforms</h2><p>Meta Platforms may be trying to bank on the emergence of the metaverse, but that&#39;s not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.</p><p>Proof of the company&#39;s resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.</p><p>Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there&#39;s no real competition out there that Facebook faces, which is why it&#39;s such a safe investment for the foreseeable future.</p><p>Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company&#39;s net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.</p><p>It&#39;s almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT":"雅培","BK4525":"远程办公概念","BK4566":"资本集团","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4524":"宅经济概念","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201269899","content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008271112,"gmtCreate":1641474365422,"gmtModify":1676533618682,"author":{"id":"3572826093389291","authorId":"3572826093389291","name":"Tadalada","avatar":"https://static.tigerbbs.com/b72694826dfd7043f27335bde2e7e70b","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":5,"crmLevelSwitch":0,"idStr":"3572826093389291","authorIdStr":"3572826093389291"},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008271112","repostId":2201269899,"repostType":4,"repost":{"id":"2201269899","kind":"highlight","pubTimestamp":1641474113,"share":"https://ttm.financial/m/news/2201269899?lang=&edition=fundamental","pubTime":"2022-01-06 21:01","market":"us","language":"en","title":"2 Safe Growth Stocks to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","media":"Motley Fool","summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","content":"<html><head></head><body><p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.</p><p>However, there are two growth stocks that look to be fairly safe bets to do well this year: <b>Abbott Laboratories </b>(NYSE:ABT) and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB). These industry giants don&#39;t lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.</p><h2>1. Abbott Laboratories</h2><p>Abbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests &#34;performed at equivalent sensitivity as other variants.&#34;</p><p>For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company&#39;s business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.</p><p>When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor&#39;s offices and hospitals are back to their normal operations.</p><p>Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the <b>S&amp;P 500</b> has increased by a more modest 281%. Even though Abbott has already outperformed the S&amp;P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.</p><h2>2. Meta Platforms</h2><p>Meta Platforms may be trying to bank on the emergence of the metaverse, but that&#39;s not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.</p><p>Proof of the company&#39;s resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.</p><p>Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there&#39;s no real competition out there that Facebook faces, which is why it&#39;s such a safe investment for the foreseeable future.</p><p>Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company&#39;s net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.</p><p>It&#39;s almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT":"雅培","BK4525":"远程办公概念","BK4566":"资本集团","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4524":"宅经济概念","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201269899","content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9008273751,"gmtCreate":1641474269664,"gmtModify":1676533618681,"author":{"id":"3585044510958477","authorId":"3585044510958477","name":"Jer_Soul","avatar":"https://static.tigerbbs.com/1e2cafce52f5cbb77f8b4a073c7be9a3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3585044510958477","authorIdStr":"3585044510958477"},"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008273751","repostId":2201269899,"repostType":4,"repost":{"id":"2201269899","kind":"highlight","pubTimestamp":1641474113,"share":"https://ttm.financial/m/news/2201269899?lang=&edition=fundamental","pubTime":"2022-01-06 21:01","market":"us","language":"en","title":"2 Safe Growth Stocks to Buy for 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=2201269899","media":"Motley Fool","summary":"These two stocks have performed well in recent years and there's no reason to doubt they will continue growing.","content":"<html><head></head><body><p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.</p><p>However, there are two growth stocks that look to be fairly safe bets to do well this year: <b>Abbott Laboratories </b>(NYSE:ABT) and <b><a href=\"https://laohu8.com/S/FB\">Meta Platforms</a> </b>(NASDAQ:FB). These industry giants don&#39;t lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.</p><h2>1. Abbott Laboratories</h2><p>Abbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests &#34;performed at equivalent sensitivity as other variants.&#34;</p><p>For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company&#39;s business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.</p><p>When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor&#39;s offices and hospitals are back to their normal operations.</p><p>Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the <b>S&amp;P 500</b> has increased by a more modest 281%. Even though Abbott has already outperformed the S&amp;P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.</p><h2>2. Meta Platforms</h2><p>Meta Platforms may be trying to bank on the emergence of the metaverse, but that&#39;s not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.</p><p>Proof of the company&#39;s resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.</p><p>Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there&#39;s no real competition out there that Facebook faces, which is why it&#39;s such a safe investment for the foreseeable future.</p><p>Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company&#39;s net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.</p><p>It&#39;s almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Safe Growth Stocks to Buy for 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Safe Growth Stocks to Buy for 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4554":"元宇宙及AR概念","BK4553":"喜马拉雅资本持仓","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","ABT":"雅培","BK4525":"远程办公概念","BK4566":"资本集团","BK4082":"医疗保健设备","BK4508":"社交媒体","BK4524":"宅经济概念","BK4527":"明星科技股","BK4077":"互动媒体与服务","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4504":"桥水持仓","BK4548":"巴美列捷福持仓"},"source_url":"https://www.fool.com/investing/2022/01/06/2-safe-growth-stocks-to-buy-for-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201269899","content_text":"This new year could be a volatile one. Between inflation, rising interest rates, and a new coronavirus variant to worry about, the path ahead is about as clear as mud. Trying to predict which stocks will be good buys for 2022 is no easy task.However, there are two growth stocks that look to be fairly safe bets to do well this year: Abbott Laboratories (NYSE:ABT) and Meta Platforms (NASDAQ:FB). These industry giants don't lack growth opportunities and they can also offer investors plenty of security along with some strong long-term returns.1. Abbott LaboratoriesAbbott Laboratories has benefited from a boost in sales due to COVID-19 testing since the start of the pandemic. Its rapid point-of-care test, BinaxNOW, has made it easy for health officials to stay on top of rising case numbers and for people to test themselves at home. And Abbott says that even for the new omicron variant, its tests \"performed at equivalent sensitivity as other variants.\"For an investor concerned about omicron, Abbott can be a great way to hedge against that risk. And even if someone is more optimistic that COVID-19 will go away and that the economy will return to normal this year, then Abbott can still prove to be a solid investment in 2022. The company's business did get a $1.9 billion boost in revenue for the third quarter (ended Sept. 30, 2021), bringing its top line up to $10.9 billion. However, even without the testing sales, Abbott still would have performed well as it generated growth across all of its reporting segments.When excluding COVID-19 testing sales, its diagnostics segment still generated revenue growth of over 14.1%. Other areas of its business, including pharmaceuticals, medical devices, and nutrition, grew at rates of 15.1%, 14.6%, and 9.6%, respectively. And those are all areas that could rise in a return to normal where doctor's offices and hospitals are back to their normal operations.Over the past decade, Abbott has proven to be a safe healthcare stock to hold, rising more than 416% during that time while the S&P 500 has increased by a more modest 281%. Even though Abbott has already outperformed the S&P 500 over the past 10 years it still has even more potential to continue outpacing it in the future.2. Meta PlatformsMeta Platforms may be trying to bank on the emergence of the metaverse, but that's not why the stock is on this list. For now, the tech stock remains a great buy for its social media platforms that continue to drive significant traffic.Proof of the company's resilience and stability is evident through the growth in its daily active users (DAUs). The company reported 1.9 billion DAUs for the period ended Sept. 30, 2021, a 19% increase from 1.6 billion just two years ago, before the pandemic. And during each one of those periods in between, DAUs steadily grew. Those numbers do not include Instagram or WhatsApp, demonstrating that even amid the Cambridge Analytica scandal and problems with preventing the spread of fake news, users have continued to flock to Facebook in recent years.Meta Platforms can be a good stock to buy for investors who are worried about COVID-19 and people being stuck at home. But even if the economy is fully reopened the stock could continue to fare well as Facebook users would be able to post selfies of all the places they can travel to again. Also, there's no real competition out there that Facebook faces, which is why it's such a safe investment for the foreseeable future.Plus, the business makes tons of money. Its gross margin has been more than 80% of revenue in each of the past five years, and the company's net profit margin is regularly north of 30%. Meta Platforms has also generated $35.8 billion in free cash flow over the trailing 12 months. With that kind of money rolling in, the company is in an excellent position to acquire more businesses or pursue any growth opportunities that may come up in the future.It's almost been 10 years since this growth stock first went public, and since then, its shares have soared more than 785%. Investors can likely expect even more growth in the years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":46,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}